Thursday, May 8, 2025

Latest

Revive Therapeutics Sees FDA Recommend Phase 3 For COVID-19 Related Study Of Bucillamine

Revive Therapeutics (CSE: RVV) announced major news this morning related to its ongoing study of Bucillamine, with the US Food and Drug Administration recommending that the company proceed straight to a phase three confirmatory clinical trial to evaluate Bucillamine for the treatment of patients with mild-moderate COVID-19 due to the SARS-CoV-2 infection.

The news is significant as it means that Revive will be able to skip over the phase two clinical study portion of the FDA’s process, enabling the product to get to market sooner than expected if proven effective against the infectious disease. The push to phase three on the study of Bucillamine will enable the company to expeditiously evaluate the safety and efficacy of the drug.

In addition to the recommendation provided, the FDA also provided guidance on the study design and outcome measures for the phase 3 study. More importantly, the FDA identified that as a result of Revive’s previous work with the drug on the treatment of gout, the data provided from that study could be used to skip over phase 1 and 2 of the clinical study process. The firms contract research team, Pharm-Olam, is actively working towards assembling the final investigation new drug (IND) for submission to the FDA within the next 60 days, after which the firm will begin its phase 3 trials.

Revive Therapeutics last traded at $0.18 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

One Response

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

Brazil Potash Secures Funding In Support Of US$2.5 Billion Autozales Project

Giant Mining Encounters Native Copper As Hole MHB-34 Hits 563 Metres Depth

Related News

US New Coronavirus Cases Continue to Break Daily Records

Despite the eagerness amongst Americans to return to the bustling activity once seen before the...

Friday, July 10, 2020, 05:31:00 PM

Relay Medical Forms Joint Venture To Provide COVID-19 Pandemic Response Tech

Relay Medical Corp (CSE: RELA) has formed a joint venture with that of Fio Corp...

Wednesday, August 19, 2020, 08:12:02 AM

Remark Holdings Vs. Internet of Things Inc: A Thermal Fever Fighting Device Comparison

Remark Holdings (NASDAQ: MARK) has been on a wild run as of late since announcing...

Wednesday, May 13, 2020, 09:02:30 AM

Datametrex Awarded Tender To Supply 2,000 COVID-19 Test Kits

Datametrex AI (TSXV: DM) appears to have a sales pipeline in the mining sector. This...

Friday, June 5, 2020, 08:43:21 AM

Mnuchin: Fed to Make $4 Trillion Dollars of Loans Available to Small Businesses, Plus $3k Cheque to Families

Sweet Jesus! This morning US Treasury Secretary Steven Mnuchin was on Fox Business and said...

Sunday, March 22, 2020, 11:41:32 AM